Mas sobre ARNA, http://beta.fool.com/beatlesforever/2012/12/11/arena-pressures-short-sellers-as-hedge-fund-owner-/18408/?logvisit=y&published=2012-12-11&source=eptcnnlnk0000001
curioso artículo sobre ARNA, VVUS y hasta Adam Feuerstein tb metido por ahí
esto es lo que más me gusta del artículo, además de compartirlo, veremos a ver cuando despega ARNA y nos da las alegrias que esperamos desde hace meses
"Wall Street had it wrong with Arena just as it did about Vivus, but inversely. This mistake resulted in astronomical short interest, which was confronted with the painful fact of a strong FDA approval of Belviq last June. Since then, Arena short sellers were caught between a rock and a hard place with few options:
1) Cover and incur a potential billion dollar loss;
2) Short more shares in hope of
a) increasing sales-basis
b) spooking retail holders to sell.
"
ARNA, 2ª indice Rusell 3000, por "Second on the list is Arena Pharmaceuticals (ARNA) with a gain of 367.4%."
fuente: http://seekingalpha.com/article/1056711-russell-3000-top-performing-stocks-year-to-date?source=yahoo
AMRN, haciendo camino hacia su comercialización
http://finance.yahoo.com/news/amarin-announces-additional-vascepa-r-123000507.html
"today announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc. (Slanmhor)"
"Slanmhor, based in Halifax, Nova Scotia, Canada, is led by CEO Robert Orr, a pioneer and industry leader in the omega-3 manufacturing industry and the former Chairman and CEO of ONC, the world's largest supplier of concentrated omega-3 fatty acid products"
jefferies mantiene BUY y PO a 28
http://www.streetinsider.com/Analyst+Comments/Jefferies+Maintains+Bullish+Stance+on+Amarin+%28AMRN%29+Despite+Self+Commercialization+News/7931803.html?si_client=st